The Latest Cardiac and Vascular News
AWANS, Belgium–(BUSINESS WIRE)–Miracor Medical SA (Miracor Medical) has announced the award of the CE Mark for its latest generation of PiCSO Impulse Catheter and PiCSO Impulse Console, which is indicated for the treatment of anterior STEMI patients. The new system features improvements in ease of use. PiCSO therapy is delivered […]
NEW YORK–(BUSINESS WIRE)–TARA Biosystems, Inc., a company generating in vitro human biology to increase the success of cardiac disease drug discovery and development, today announced a $10 million Series A2 financing. This financing will be used to scale TARA’s cardiac tissue engineering platform technology and advance its drug discovery programs. New investors […]
he Evolut TAVI Platform Receives New Indication for Patients with Bicuspid Aortic Valves at Extreme, High or Intermediate Risk of Surgical Mortality DUBLIN, June 22, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) mark and European launch of the Evolut™ Transcatheter […]
Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New Observations Show Improvements in Left Atrial Volume and Function, Key Prognostic Indicators of Atrial Fibrillation Additional Nonclinical Studies Also Presented Demonstrating Danicamtiv’s Differentiated Mechanistic Profile Including Direct […]
CALGARY, Alberta, June 22, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce that the U.S. Food & Drug Administration (FDA) has accepted its BETonMACE2 clinical plan as a registration enabling study with positive implications for Resverlogix and its ongoing partnership discussions. Key written development points from […]
MUMBAI, India, June 16, 2020 /PRNewswire/ — MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent restenosis. The approval applies to a broad […]
DANVERS, Mass.–(BUSINESS WIRE)–Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to improve patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization. […]
MONTREAL, June 15, 2020 /PRNewswire/ – Puzzle Medical Devices Inc., (www.puzzlemed.com) announces the closure of its first convertible debenture financing round led by Canadian entrepreneur Pascal Labrecque. Other participants include a United States venture capital firm, entrepreneurs and interventional cardiologists practicing in Canada, the United States and Europe. This investment follows the successful completion of Puzzle Medical’s first preclinical studies […]
Using wearables and devices, physicians can incorporate clinical data into telehealth visits to offer complete remote health management. NEW YORK, June 15, 2020 /PRNewswire/ — The American College of Cardiology (ACC) and Heartbeat Health, the first telemedicine and virtual care platform built by cardiologists for cardiologists, are joining forces to transform telehealth into […]
DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company’s investigational device exemption application to start an early feasibility study with a first-in-human trial of the 9 French (Fr) Impella ECP™ heart pump. Impella ECP, which stands for expandable cardiac power, will be […]
